To this end, we employed IFNGR1−/− mice and adoptive transfer of total IFNGR1−/− T cells to tumor-bearing mice, and found that loss of IFNGR1 in T cells completely abrogated the efficaciousness of combined anti-CTLA-4 and anti-PD-1 therapy [92]. The gene discussed is CTLA4; the disease is neoplasm.